Patents Examined by Howard E. Schain
  • C-terminal peptide or protein sequencing reagent and method
    Patent number: 5180807
    Abstract: A carboxy terminal protein sequencing process is disclosed which utilizes phosphoroisothiocyanatidate for the derivatization step.
    Type: Grant
    Filed: December 3, 1991
    Date of Patent: January 19, 1993
    Assignee: City of Hope
    Inventors: Jerome M. Bailey, John E. Shively
  • Method for the treatment of ATLL and the inhalant for the same
    Patent number: 5171567
    Abstract: An improved method for treating or curing ATL, with lowered side effects, comprising administering an effective amount of interferon-.gamma. to a mammalian species in need of such treatment via respiratory tract by inhalation, wherein recommended is that a single dose of said interferon-.gamma. to human adults is 1,000,000 JRU to 6,000,000 JRU and the single dose is repeated at a frequency between once-a-week and twice-a-day.
    Type: Grant
    Filed: March 15, 1990
    Date of Patent: December 15, 1992
    Assignee: Shionogi & Co., Ltd.
    Inventor: Mitsutoshi Tara
  • Oral pharmaceutical composition containing a polyethylene glycol-immunoglobulin G conjugate for reconstitution of secretory immunity and method of reconstituting secretory immunity
    Patent number: 5169627
    Abstract: Polyethylene glycol serum immunoglobulin conjugates exhibit substantial rstance to degradation by intestinal enzyme while retaining their immuno-activity. Thus, PEG-IgG or PEG-IgA conjugates can be used as orally administered therapeutics to treat patients with gastrointestinal immunodeficiency to reconstitute secretory immunity. Preferred conjugates are made by reacting activated PEG and IgG in ratios of from 1:5 to 1:1000 such that less than about 27% of the IgG lysine residues are bonded to the PEG. The conjugates are advantageously formulated into a pharmaceutical composition comprising the conjugate and a pharmaceutically acceptable oral carrier. Particularly for administration to infants, a preferred oral carrier is milk.
    Type: Grant
    Filed: October 28, 1991
    Date of Patent: December 8, 1992
    Assignee: Mount Sinai School of Medicine of the City University of New York
    Inventor: Charlotte Cunningham-Rundles
  • Culturing method, system and apparatus for cell culture
    Patent number: 5166067
    Abstract: A culturing method and system are disclosed in which a cell culture broth in withdrawn from a culturing apparatus to a filteration apparatus. The withdrawn broth in brought into contact with a membrane for precision filteration. Then a non-toxic gas is brown into the broth, while filtering the broth to separate the cells and breaking foams occurring on the surface of the broth due to gas bubbling. The separated cells are returned to the vessel and the filterate is withdrawn from the filteration apparatus.The method and system have such advantages that a perfusion culture of a long period of time can be realized because the clogging of the filteration membrane is effectively prevented.
    Type: Grant
    Filed: November 29, 1989
    Date of Patent: November 24, 1992
    Assignee: Hitachi, Ltd.
    Inventors: Masahiko Ishida, Ryoichi Haga, Harumi Matsuzaki
  • Method for treating condyloma acuminatum with interferon
    Patent number: 5165921
    Abstract: A pharmaceutical composition which includes human alpha-interferon, sodium dodecyl sulfate and a pharmaceutically acceptable vehicle is described. A method of using the pharmaceutical composition as a topical therapeutic agent in the treatment of condyloma acuminata is also provided.
    Type: Grant
    Filed: March 21, 1991
    Date of Patent: November 24, 1992
    Assignee: National Geno Sciences, Inc.
    Inventors: Orekonde Ganesh, William E. Stewart
  • Treatment of allergic rhinitis
    Patent number: 5166134
    Abstract: A method for the prophylaxis or direct treatment of allergic rhinitis which comprises nasally administering to a patient an effective amount of a serine protease inhibitor which inhibits mast cells, neutrophiles or T-cells or binds with their mediators.
    Type: Grant
    Filed: June 4, 1991
    Date of Patent: November 24, 1992
    Inventors: John Lezdey, Allan J. Wachter
  • Use of relaxin in cardiovascular therapy
    Patent number: 5166191
    Abstract: The invention concerns the use of relaxin in the cardiovascular therapy, and specifically in the treatment of acute and chronic heart failure.
    Type: Grant
    Filed: August 19, 1991
    Date of Patent: November 24, 1992
    Assignee: Genentech, Inc.
    Inventors: Michael Cronin, Phyllis L. Osheroff, David G. Ward
  • Recombinant aprotinin variants genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof
    Patent number: 5164482
    Abstract: An aprotinin with a deletion of the amino acid proline in position 2 or an addition of alanine-(-2)- glutamine-(-1). Such aprotinin is useful as an active ingredient in medicaments.
    Type: Grant
    Filed: August 24, 1990
    Date of Patent: November 17, 1992
    Assignee: Bayer Aktiengesellschaft
    Inventors: Jurgen Ebbers, Dietrich Horlein, Michael Schedel, Rathindra Das
  • Treatment for osteoporosis using growth hormone releasing factor (GRF) in combination with parathyroid hormone (PTH)
    Patent number: 5164368
    Abstract: A method of treating osteoporosis, especially postmenopausal osteoporosis, by administering on a periodic but regular basis to a patient growth hormone releasing factor, GRF(1-44)-NH.sub.2, or a biologically active analog thereof, and concurrently administering parathyroid hormone, PTH(1-34)-NH.sub.2 and continuing the administration until bone mass increases and the patient's calcium balance becomes positive and indicates a mineral accumulation in the skeleton.
    Type: Grant
    Filed: November 4, 1991
    Date of Patent: November 17, 1992
    Inventor: Robert R. Recker
  • Therapeutic agent for diabetic gangrene comprising factor XIII
    Patent number: 5164373
    Abstract: An agent for the therapy of diabetic gangrene is described containing blood coagulation factor XIII as the active ingredient.
    Type: Grant
    Filed: February 15, 1991
    Date of Patent: November 17, 1992
    Assignee: Hoechst Japan Limited
    Inventors: Masahiko Shikano, Satoshi Tanaka, Masao Ikdea, Hiroshi Nin
  • Method for isolating IgAs in the feces
    Patent number: 5155213
    Abstract: A method for isolating the IgAs in the feces of animals and humans including the steps of placing said feces in a container with a buffer solution, homogenizing the feces in a phosphate buffer saline solution thereby forming a homogenized solution, separating the solids from the homogenized solution leaving a clear solution and chemically precipitating substantially all material contained in the clear solution with the exception of the IgAs through the use of protamine. The method produces a sufficient amount of IgAs for diagnostic and treatment purposes, if necessary.
    Type: Grant
    Filed: October 28, 1991
    Date of Patent: October 13, 1992
    Inventor: Eloy Padron
  • Method for solubilization and naturation of somatotropins utilizing sulfolane
    Patent number: 5151501
    Abstract: The present invention relates to a process for solubilization and naturation of somatotropins utilizing a combination of sulfolane and an aqueous alkaline solution. By utilizing the process of the present invention, enhanced yields of end product result.
    Type: Grant
    Filed: December 20, 1991
    Date of Patent: September 29, 1992
    Assignee: American Cyanamid Company
    Inventor: Kevin M. McCoy
  • Production method for protein-containing composition
    Patent number: 5151499
    Abstract: A method of producing a virus-inactivated protein-containing composition from a protein-containing composition which may be contaminated with virus. The method according to the present invention permits production of pharmaceutically safer virus-inactivated protein preparations without spoiling the protein activity.
    Type: Grant
    Filed: January 12, 1990
    Date of Patent: September 29, 1992
    Assignee: The Green Cross Corporation
    Inventors: Shoju Kameyama, Kenmi Miyano, Motonori Hashimoto, Kazuo Takechi, Takao Ohmura, Yutaka Hirao, Yahiro Uemura, Kazumasa Yokoyama
  • Bisalkoxyphosphinyl compounds as renin inhibitors
    Patent number: 5149692
    Abstract: The invention concerns novel renin-inhibitory peptides which are useful for treating renin-associated hypertension, congestive heart failure, hyperaldosteronism, glaucoma, and diseases caused by retroviruses including HTLV-I, -II, -III. Processes for preparing the peptides, novel intermediates useful in the preparation thereof, compositions containing them, and methods of using them are included. Also included is a diagnostic method which uses the compounds to determine the presence of renin-associated hypertension, congestive heart failure, or hyperaldosteronism.
    Type: Grant
    Filed: December 21, 1989
    Date of Patent: September 22, 1992
    Assignee: Warner-Lambert Company
    Inventors: Annette M. Doherty, Harriet W. Hamilton, Bruce A. Steinbaugh
  • Issue repair and regeneration through the use of platelet derived growth factor (PDGF) in combination with dexamethasone
    Patent number: 5149691
    Abstract: Disclosed is a method for the regeneration of tissue, the treatment of external wounds and the treatment of periodontal disease comprised of applying to the afflicted tissue a pharmaceutically effective amount of a composition comprised of platelet-derived growth factor and dexamethasone.
    Type: Grant
    Filed: March 12, 1991
    Date of Patent: September 22, 1992
    Assignee: Creative BioMolecules, Inc.
    Inventor: Robert B. Rutherford
  • TGF-B compositions and method
    Patent number: 5147854
    Abstract: Transforming growth factor-beta (TGF-beta) is enhanced in its therapeutic activity by utilizing it in combination with a synergistic effective amount of a polyunsaturated fatty acid (PUFA). In a preferred embodiment, type 1 transforming growth factor beta (TGF-.sym.1) exhibits enhanced anti-neoplastic activity when utilized in combination with an n=3 or n=6 polyunsaturated fatty acid. Examples of suitable unsaturated fatty acids include linoleic, alpha-linolenic, arachidonic, gamma-linolenic, dihomogammalinolenic, eicosapentaenoic and docosahexaenoic. Combinations of these agents effectively kill various human carcinoma and melanoma cell lines under defined conditions in vitro at picomolar concentrations of TGF-.beta.1 and at .mu.g/ml concentrations of the polyunsaturated fatty acid, levels where the respective two agents acting alone are ineffective.
    Type: Grant
    Filed: May 22, 1990
    Date of Patent: September 15, 1992
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Michael J. Newman
  • Method and means for extending the host range of insecticidal proteins
    Patent number: 5143905
    Abstract: The invention relates to a method for increasing the host range or toxicity of an insecticidal protein exerting its activity via interaction with the gut epithelium of insects within its host range, by delivering the insecticidal protein to the gut epithelium of a target insect with the aid of an other, targeting protein capable of binding to the gut epithelium of the target insect. The targeting protein may, for example, be of viral origin or, alternatively, may be a bacterial protein or protein domain having high affinity for the lipid components of membranes.
    Type: Grant
    Filed: May 3, 1990
    Date of Patent: September 1, 1992
    Assignee: The Regents of the University of California
    Inventors: Natarajan Sivasubramanian, Brian A. Federici
  • Oxidative folding of peptide and protein substrates using hydrocarbon sulfoxides
    Patent number: 5144006
    Abstract: Method for oxidative folding of peptide and protein substrates to form disulfide bonds using dimethyl sulfoxide and other equivalent sulfoxides as mild oxidizing agents.
    Type: Grant
    Filed: June 13, 1991
    Date of Patent: September 1, 1992
    Assignee: The Rockefeller University
    Inventor: James P. Tam
  • Protein partial degradation product, process for preparing it and its use
    Patent number: 5138038
    Abstract: Novel protein partial degradation products obtainable from grain proteins such as wheat protein, maize protein, soya bean protein, etc., by specific degradation treatments, which are useful as a quality-improving agent for various food stuffs, a surface active agent, a dispersing agent for particles, etc.
    Type: Grant
    Filed: October 4, 1990
    Date of Patent: August 11, 1992
    Assignee: Katayama Chemical Works Co., Ltd.
    Inventors: Sakae Katayama, Atsushi Tsuda, Kenzi Hanno
  • Process for preparing peptide synthons
    Patent number: 5138037
    Abstract: The present invention relates to a process for preparing optically active synthons, in which an oxygen-silylated amino acid or peptide having a protected nitrogenous group, is activated by a non-coordinated halogenated phosphorus derivative and is condensed with an N-silyl amino acid or peptide in which the acid group is protected.
    Type: Grant
    Filed: March 5, 1991
    Date of Patent: August 11, 1992
    Assignee: Rhone-Poulenc Chimie
    Inventors: Robert Jacquier, Jean Verducci, Virginie Pevere